INFO SHEET

PDO Monolayer for Inflammatory Bowel Disease (IBD)

Existing treatment protocols (such as 5-ASAs and anti-TNFs) for inflammatory bowel disease (IBD) focus on restoring barrier function and promoting epithelial healing. Nevertheless, 40% of IBD patients do not respond to these treatments, underscoring the need to identify new therapeutic targets. Traditional preclinical models, including non-primary monocultures and non-human in vivo models, lack translational relevance as they fail to faithfully replicate the human intestinal environment. A patient-derived organoid (PDO) monolayer serves as an in vitro system derived from individual patients, arranged in a single, polarized layer enriched with various intestinal cell types, effectively mimicking in vivo organ physiology. Organoid monolayers permit assessment of barrier function on both the apical and basal sides of the epithelium, providing insights into the response to inflammatory challenges.

Acknowledging the industry’s demand for rapid and physiologically relevant data, we have developed IntegriGut Screen, a service that uses PDO Monolayer to provide you with high-quality human data on epithelial barrier function, cytotoxicity, and cytokine release for IBD drug discovery and development.

Download this Infosheet to discover:

• The development process of PDO Monolayers for simulating epithelial barrier damage in IBD 
• An introduction to IntegriGut Efficacy Screen, with details on the strategic screen design, experimental timeline, and available readouts 
• An introduction to IntegriGut Biobank Screen, with details on the IBD biobank